A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder
暂无分享,去创建一个
S. Southwick | D. Charney | N. V. Van Dam | D. Iosifescu | S. Costi | J. Murrough | B. Iacoviello | K. Collins | A. Mathé | A. Feder | M. Parides | S. Horn | M. Kautz | S. Sayed | Marin M. Kautz
[1] D. Charney,et al. Neuropeptide Y, resilience, and PTSD therapeutics , 2017, Neuroscience Letters.
[2] E. Sabban,et al. Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder , 2016, Neuropeptides.
[3] F. Reichmann,et al. Neuropeptide Y: A stressful review , 2016, Neuropeptides.
[4] C. Marmar,et al. Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials. , 2015, JAMA.
[5] L. Simms,et al. Confirmatory factor analyses of DSM-5 posttraumatic stress disorder symptoms in psychiatric samples differing in Criterion A status. , 2015, Journal of anxiety disorders.
[6] Xinfeng Liu,et al. Intranasal delivery: circumventing the iron curtain to treat neurological disorders , 2015, Expert opinion on drug delivery.
[7] J. Zohar,et al. Diurnal Fluctuations in HPA and Neuropeptide Y-ergic Systems Underlie Differences in Vulnerability to Traumatic Stress Responses at Different Zeitgeber Times , 2015, Neuropsychopharmacology.
[8] M. Lauková,et al. Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats. , 2014, Endocrinology.
[9] P. Horn,et al. Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder , 2014, Psychoneuroendocrinology.
[10] L. Pucillo,et al. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model , 2014, European Neuropsychopharmacology.
[11] C. Nievergelt,et al. Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe , 2013, Psychoneuroendocrinology.
[12] G. Griebel,et al. 50 years of hurdles and hope in anxiolytic drug discovery , 2013, Nature Reviews Drug Discovery.
[13] T. Geracioti,et al. Neuropeptide Y and posttraumatic stress disorder , 2013, Molecular Psychiatry.
[14] M. Lauková,et al. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats , 2013, Neuroscience.
[15] E. Nestler,et al. Neurobiology of resilience , 2012, Nature Neuroscience.
[16] A. Misra,et al. Drug delivery systems from nose to brain. , 2012, Current pharmaceutical biotechnology.
[17] T. Montine,et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .
[18] D. Charney,et al. Central functions of neuropeptide Y in mood and anxiety disorders , 2011, Expert opinion on therapeutic targets.
[19] P. Horn,et al. Low Cerebrospinal Fluid Neuropeptide Y Concentrations in Posttraumatic Stress Disorder , 2009, Biological Psychiatry.
[20] J. Lee,et al. Dose Escalation Methods in Phase I Cancer Clinical Trials , 2009, Journal of the National Cancer Institute.
[21] Ahmad R. Hariri,et al. Genetic variation in human NPY expression affects stress response and emotion , 2008, Nature.
[22] M. Śmiałowska,et al. The Effect of Intrahippocampal Injection of Group II and III Metobotropic Glutamate Receptor Agonists on Anxiety; the Role of Neuropeptide Y , 2007, Neuropsychopharmacology.
[23] R. Yehuda,et al. Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping , 2006, Biological Psychiatry.
[24] A. Steiger,et al. Neuropeptide Y (NPY) shortens sleep latency but does not suppress ACTH and cortisol in depressed patients and normal controls , 2006, Psychoneuroendocrinology.
[25] D. York,et al. Effects of Altered Amygdalar Neuropeptide Y Expression on Anxiety-Related Behaviors , 2005, Neuropsychopharmacology.
[26] Olga V. Demler,et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.
[27] R. G. Thorne,et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration , 2004, Neuroscience.
[28] J. Born,et al. Manipulating central nervous mechanisms of food intake and body weight regulation by intranasal administration of neuropeptides in man , 2004, Physiology & Behavior.
[29] M. Heilig. The NPY system in stress, anxiety and depression , 2004, Neuropeptides.
[30] D. Charney,et al. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. , 2004, The American journal of psychiatry.
[31] J. Born,et al. NPY attenuates positive cortical DC-potential shift upon food intake in man , 2003, Psychoneuroendocrinology.
[32] Jan Born,et al. Sniffing neuropeptides: a transnasal approach to the human brain , 2002, Nature Neuroscience.
[33] J. Harro,et al. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y , 2002, Neuroscience & Biobehavioral Reviews.
[34] H. Pincus,et al. The DSM-IV Text Revision: rationale and potential impact on clinical practice. , 2002, Psychiatric services.
[35] R. Quirion,et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] A. Steiger,et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men , 2000, Neuropharmacology.
[37] A. Bannon,et al. Behavioral characterization of neuropeptide Y knockout mice , 2000, Brain Research.
[38] C. A. Morgan,et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training , 2000, Biological Psychiatry.
[39] C. A. Morgan,et al. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD , 2000, Biological Psychiatry.
[40] L. Edvinsson,et al. Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose. , 1999, American journal of respiratory and critical care medicine.
[41] Lacroix Js,et al. Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients , 1996 .
[42] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[43] A. Beck,et al. Further evidence for the validity of the beck anxiety inventory with psychiatric outpatients , 1993 .
[44] Stephen Senn,et al. Cross-over trials in clinical research , 1993 .
[45] M. Kaliner,et al. Neuropeptide Y is a vasoconstrictor in human nasal mucosa. , 1992, Journal of applied physiology.
[46] S. Orr,et al. Psychophysiologic assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. , 1987, Archives of general psychiatry.
[47] T. Crow,et al. Neuropeptide Y distribution in human brain , 1983, Nature.
[48] J. Zohar,et al. The Neuropeptide Y (NPY)-ergic System is Associated with Behavioral Resilience to Stress Exposure in an Animal Model of Post-Traumatic Stress Disorder , 2012, Neuropsychopharmacology.
[49] Daniel S. Weiss,et al. The Impact of Event Scale: Revised , 2007 .
[50] J. Davidson,et al. Clinician‐administered PTSD scale: A review of the first ten years of research , 2001, Depression and anxiety.
[51] B. Mosimann,et al. Attenuation of allergen-evoked nasal responses by local pretreatment with exogenous neuropeptide Y in atopic patients. , 1996, The Journal of allergy and clinical immunology.
[52] C. Spielberger,et al. Manual for the State-Trait Anxiety Inventory , 1970 .